Cybin Inc. (HELP)

TheFly reported on July 1 that Canaccord analyst Sumant Kulkarni lowered the price target on HELP to $42 from $45 while maintaining a Buy rating on the shares.

As the psychedelic drug industry shifts from a speculative niche to a potential part of mainstream healthcare, investors have started to keep a careful eye on it.

The AdvisorShares Psychedelics ETF, a fund that primarily invests in the psychedelic drugs sector, is up 31% over the past year. That almost doubles the S&P 500’s 16% gain over the same timeframe.

TheFly reported on February 2 that Jefferies initiated coverage of HELP with a Buy rating and a $22 price target and also highlighted significant upside potential.